Abstract
Amplification of chromosome arm 3q is the most consistent aberration in cervical cancer, and is implicated in the progression of dysplastic uterine cervical cells into invasive cancer. The present study employed the ‘positional candidate gene’ strategy to determine the contribution of PIK3CA, which is located in 3q26.3, in cervical tumorigenesis. PIK3CA is known to be involved in the PI 3-kinase/AKT signaling pathway, which plays an important role in regulating cell growth and apoptosis. The results of comparative genomic hybridization show that the 3q26.3 amplification was the most consistent chromosomal aberration in primary tissues of cervical carcinoma, and a positive correlation between an increased copy number of PIK3CA (detected by competitive PCR) and 3q26.3 amplification was found in tumor tissues and in cervical cancer cell lines. In cervical cancer cell lines harboring amplified PIK3CA, the expression of gene product (p110α) of PIK3CA was increased, and was subsequently associated with high kinase activity. In addition, transformation phenotypes in these lines, including increased cell growth and decreased apoptosis, were found to be significantly affected by the treatment of specific PI 3-kinase inhibitor, suggesting that increased expression of PIK3CA in cervical cancer may result in promoting cell proliferation and reducing apoptosis. These evidences support that PIK3CA is an oncogene in cervical cancer and PIK3CA amplification may be linked to cervical tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A and Nussbaum RL . 1999 J Biol Chem 274: 10963–10968
Cantley, LC and Neel BG . 1999 Proc Natl Acad Sci USA 96: 4240–4245
Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM and Vogt PK . 1997 Science 276: 1848–1850
Chu TY, Shen CY, Lee HS and Liu HS . 1999 Genes Chromosom Cancer 24: 127–134
Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, Venzon DJ, Shearer GM, De Palo G and Clerici E . 1997 J Natl Cancer Inst 89: 245–250
Datta SR, Brunet A and Greenberg ME . 1999 Genes Dev 13: 2905–2927
Diehl JA, Cheng M, Roussel MF and Sherr CJ . 1998 Genes Dev 12: 3499–3511
Donnellan R and Chetty R . 1999 FASEB J 13: 773–780
Ebert AD, Wechselberger C, Frank S, Wallace-Jones B, Seno M, Martinez-Lacaci I, Bianco C, De Santis M, Weitzel HK and Salomon DS . 1999 Cancer Res 59: 4502–4505
Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CV and Villeponteau B . 1995 Science 269: 1236–1241
Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, Weinberg RA and Sicinski P . 1999 Cell 97: 767–777
Imani F, Rager KJ, Catipovic B and Marsh DG . 1997 J Biol Chem 272: 7927–7931
Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN and Hay N . 1997 Genes Dev 11: 701–713
Klippel A, Escobedo MA, Wachowicz MS, Apell G, Brown TW, Giedlin MA, Kavanaugh WM and Williams LT . 1998 Mol Cell Biol 18: 5699–5711
Ku WH, Liu IL, Yen MS, Chang Chien CC, Yue CT, Ma YY, Chang SF, Ng HT, Wu CW and Shen CY . 1997 Int J Cancer 72: 270–276
Leevers SJ, Vanhaesebroeck B and Waterfield MD . 1999 Curr Opin Cell Biol 11: 219–225
Marte BM and Downward J . 1997 Trends Biochem Sci 22: 355–358
Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN and Rosen N . 1998 J Biol Chem 273: 29864–29872
Pao CC, Tseng CJ, Lin CY, Yang FP, Hor JJ, Yao DS and Hsueh S . 1997 J Clin Oncol 15: 1932–1937
Perez-Roger I, Kim SH, Griffiths B, Sewing A and Land H . 1999 EMBO J 18: 5310–5320
Ried T, Heselmeyer-Haddad K, Blegen H, Schröck E and Auer, G . 1999 Genes Chromosom Cancer 25: 195–204
Rooney PH, Murray GI, Stevenson DA, Haites NE, Cassidy J and McLeod HL . 1999 Br J Cancer 80: 862–873
Shah KV and Howley PM . 1996 Fields Virology Fields BN, Knipe DM and Howley PM eds Lippincott-Raven Publishers Philadelphia
Shayesteh L, Lu Y, KuoWL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW . 1999 Nat Genet 21: 99–102
Siebert PD and Larrick JW . 1993 BioTechniques 14: 244–249
Tlsty TD . 1999 Nat Genet 21: 64–65
Volinia S, Hiles I, Ormondroyd E, Nizetic D, Antonacci R, Rocchi M and Waterfield MD . 1994 Genomics 24: 472–477
Acknowledgements
This study was supported by National Health Research Institutes, Taiwan, Institute of Biomedical Sciences, Academia Sinica and Chen Shuyi Cancer foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ma, YY., Wei, SJ., Lin, YC. et al. PIK3CA as an oncogene in cervical cancer. Oncogene 19, 2739–2744 (2000). https://doi.org/10.1038/sj.onc.1203597
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203597
Keywords
This article is cited by
-
Differential gene expression (DGE) analysis in persons with a history of giardiasis
AMB Express (2024)
-
Endothelial cell-specific molecule 1 drives cervical cancer progression
Cell Death & Disease (2022)
-
Hsa_circ_CSPP1/MiR-361-5p/ITGB1 Regulates Proliferation and Migration of Cervical Cancer (CC) by Modulating the PI3K-Akt Signaling Pathway
Reproductive Sciences (2020)
-
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Molecular Cancer (2019)
-
AKT overactivation can suppress DNA repair via p70S6 kinase-dependent downregulation of MRE11
Oncogene (2018)